Aiming to address demand for its weight loss drug Zepbound (tirzepatide) , Eli Lilly is selling the starting dose of the medicine in four single-use vials or one four-dose pen to self-pay customers for $299
Avexitide, which has been granted FDA breakthrough therapy designation, has shown significant effectiveness in treating Postbariatric Hypoglycemia (PBH) and congenital hyperinsulinism, and is expected to commence Phase 3 trials for PBH by early 2025
If you have a family history of certain cancers, kidney issues, a history of pancreatitis, digestion problems, or diabetic retinopathy, speak with your doctor before considering Zepbound
If we were to restrict ourselves to the early 2000s paradigm of energy drink craziness, then it certainly would be
Employers looking to add GLP-1 drug coverage specifically for weight loss to their health plans will be best-served by working in conjunction with clinical data experts who can help assess benefit design, address potential increases in drug spending, and incorporate healthcare benefits with effective behavioral modification and support programs
Hand gel isnt great against norovirus, so dont rely on it